Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum

Carmelita G Mabanta; Gloria S. Pryhuber; Geoffrey A. Weinberg; Dale Phelps

doi:10.1002/14651858.CD003744

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Analysis 1.1

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 1 CLD.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 2 Death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 3 CLD or death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 4 Side effects of erythromycin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 1 CLD.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 2 Death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 3 CLD or death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.4

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 4 Side effects of erythromycin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 CLD Show forest plot	1	75	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [0.72, 2.70]

1.1 Culture/PCR positive	1	9	Risk Ratio (M‐H, Fixed, 95% CI)	2.0 [0.18, 22.06]
1.2 Culture/PCR negative	1	66	Risk Ratio (M‐H, Fixed, 95% CI)	1.35 [0.68, 2.69]
2 Death Show forest plot	1	75	Risk Ratio (M‐H, Fixed, 95% CI)	0.64 [0.22, 1.83]

2.1 Culture/PCR positive	1	9	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.03, 11.21]
2.2 Culture/PCR negative	1	66	Risk Ratio (M‐H, Fixed, 95% CI)	0.65 [0.21, 2.00]
3 CLD or death Show forest plot	1	75	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.66, 1.69]

3.1 Culture/PCR positive	1	9	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.14, 7.10]
3.2 Culture/PCR negative	1	66	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.66, 1.72]
4 Side effects of erythromycin Show forest plot	1	75	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 1. Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection

Ir a la tabla de la revisión

Comparison 2. Erythromycin vs placebo in U. Urealyticum culture positive babies

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 CLD Show forest plot	1	28	Risk Ratio (M‐H, Fixed, 95% CI)	0.9 [0.54, 1.50]

2 Death Show forest plot	1	28	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

3 CLD or death Show forest plot	1	28	Risk Ratio (M‐H, Fixed, 95% CI)	0.9 [0.54, 1.50]

4 Side effects of erythromycin Show forest plot	1	28	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 2. Erythromycin vs placebo in U. Urealyticum culture positive babies

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet